GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Kazia Therapeutics
Shares of Kazia, an Australian oncology biotech, reflect the sector's binary risks. The price trajectory is entirely dependent on the results of clinical trials of its brain cancer treatments.
Share prices of companies in the market segment - General oncology therapy
Kazia Therapeutics is an Australian oncology company developing drugs to treat brain cancer and other difficult-to-treat tumors. We've classified it in the "General Oncology" category. The chart below shows how investors value biotech companies with niche but important developments.
Broad Market Index - GURU.Markets
Kazia Therapeutics is an Australian oncology company developing drugs to treat brain cancer and other difficult-to-treat tumors. Its focus on this niche makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Kazia compares to it.
Change in the price of a company, segment, and market as a whole per day
KZIA - Daily change in the company's share price Kazia Therapeutics
Kazia Therapeutics Limited's daily share price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its brain cancer treatments.
Daily change in the price of a set of shares in a market segment - General oncology therapy
Kazia Therapeutics is an Australian biotech company focused on brain cancer treatments. Oncology is one of the most volatile areas in the pharmaceutical industry. The chart below shows average price movements in this sector, providing context for analyzing KZIA stock.
Daily change in the price of a broad market stock, index - GURU.Markets
Kazia Therapeutics is an Australian biotech company developing drugs for the treatment of oncology. Its shares bring the dynamism of this cutting-edge field to the US market, adding an international dimension to the overall volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Kazia Therapeutics
Kazia Therapeutics' year-to-date performance is the story of its brain cancer drug development. Its 12-month market cap depends entirely on the results of a key clinical trial. Success in this complex area of oncology could be a fundamental breakthrough for the company and offer new hope to patients.
Annual dynamics of market capitalization of the market segment - General oncology therapy
Kazia, a late-stage biotech company developing cancer treatments, is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs inherent in the biotech sector, compared to big pharma.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Kazia Therapeutics, an Australian oncology company focused on treating brain cancer, is working to solve a complex medical problem. A comparison of its year-over-year market capitalization dynamics shows how clinical trial data and partnerships influence the valuation of a biotech company whose future hinges on a single key drug.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Kazia Therapeutics
Kazia is an Australian oncology company. Its monthly performance is entirely dependent on the results of its clinical trials, particularly its brain tumor drug. News of its FDA interactions and trial data are generating strong reactions.
Monthly dynamics of market capitalization of the market segment - General oncology therapy
Kazia Therapeutics is an Australian biotech company focused on developing drugs for the treatment of cancer, particularly brain tumors. Its future depends on the results of clinical trials. The oncology sector's price reflects investors' overall risk appetite, which is an important backdrop for assessing Kazia's scientific and commercial potential.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Kazia Therapeutics is an Australian oncology company whose shares are traded in the US. Its performance is entirely dependent on the results of clinical trials of its drugs. Its stock price doesn't move in sync with the market, but rather reacts to the publication of scientific data, making it independent of general economic trends, but highly volatile.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Kazia Therapeutics
Kazia Therapeutics, an Australian oncology company whose shares are also traded in the US, is dependent on global news in the cancer treatment sector. Its weekly performance reflects progress in its clinical trials, particularly for brain cancer drugs, which creates high news volatility.
Weekly dynamics of market capitalization of the market segment - General oncology therapy
Kazia Therapeutics is an Australian oncology company whose drugs are undergoing clinical trials. Weekly fluctuations in its stock price will likely reflect news of progress in these trials. A comparison with the sector will reveal how independent its path is from general trends in the biopharma industry.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Kazia Therapeutics is an Australian oncology company. Its shares are influenced less by global market trends than by the results of its clinical programs and regulatory decisions. The chart shows this dependence on internal, rather than external, factors.
Market capitalization of the company, segment and market as a whole
KZIA - Market capitalization of the company Kazia Therapeutics
Kazia Therapeutics' market capitalization chart reflects investors' assessment of its oncology drug portfolio. Its dynamics reflect the market's confidence in its leading brain cancer drug. Its high volatility is a direct response to clinical trial data, which could dramatically change the company's and patients' prospects.
KZIA - Share of the company's market capitalization Kazia Therapeutics within the market segment - General oncology therapy
Kazia Therapeutics is an Australian oncology company developing drugs for the treatment of brain cancer. Its market share in the pharmaceutical sector is small, but it is focused on a high-need area. Its market capitalization reflects the potential of its lead drug, paxilisib, which is in late-stage clinical trials.
Market capitalization of the market segment - General oncology therapy
Below is a chart reflecting the overall value of the entire oncology sector. For Kazia Therapeutics, which is developing drugs to treat brain cancer, this line represents a map of the battle against the most complex form of cancer. The rising chart shows how investors are willing to fund even the riskiest research in hopes of a breakthrough.
Market capitalization of all companies included in a broad market index - GURU.Markets
Kazia Therapeutics is an Australian oncology company developing drugs to treat brain cancer. Its market capitalization reflects its commitment to fighting one of the deadliest cancers. It represents a glial cell line of hope for patients with glioblastoma.
Book value capitalization of the company, segment and market as a whole
KZIA - Book value capitalization of the company Kazia Therapeutics
Kazia Therapeutics is an Australian oncology company developing drugs to treat brain cancer. Its book value represents its financial resources for conducting global clinical trials. How has this vital capital evolved? The chart below shows this story.
KZIA - Share of the company's book capitalization Kazia Therapeutics within the market segment - General oncology therapy
Kazia Therapeutics is an oncology company developing drugs for the treatment of brain cancer. Its clinical development requires operational infrastructure and investment in manufacturing processes at contract partners. The chart shows its share of the assets needed to bring innovative drugs to market.
Market segment balance sheet capitalization - General oncology therapy
Kazia Therapeutics is an oncology company. Pharmaceuticals, as the chart shows, are knowledge- and capital-intensive. Kazia focuses on drug development, and its capital lies in its intellectual property and R&D infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Kazia Therapeutics' assets are not factories, but a portfolio of licensed drug candidates for the treatment of brain cancer, which the company is advancing through clinical trials. The book value reflects the capital allocated to developing these promising but risky assets. The chart illustrates the scale of this Australian biotech company.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Kazia Therapeutics
Kazia Therapeutics is an Australian oncology company. Its market capitalization reflects investor valuation of its leading brain cancer drug. This is a bet on its success in clinical trials and its ability to help patients with a very complex diagnosis.
Market to book capitalization ratio in a market segment - General oncology therapy
Kazia Therapeutics is an Australian biotech focused on treating brain cancer. Its valuation on this chart is a pure bet on the success of its clinical trials in this highly complex and currently incurable disease, creating enormous potential for success.
Market to book capitalization ratio for the market as a whole
Kazia Therapeutics is an Australian biotech focused on oncology, particularly brain cancer. Its market value reflects the progress of its clinical trials and the potential of its drugs. This chart provides an insight into investor sentiment regarding risky but potentially highly rewarding biotech bets.
Debts of the company, segment and market as a whole
KZIA - Company debts Kazia Therapeutics
Kazia Therapeutics, an Australian oncology company developing drugs to treat brain cancer, is entirely dependent on external financing. Debt instruments can be used to extend its financial runway. This chart illustrates the enormous costs and risks associated with developing drugs for difficult-to-treat cancers.
Market segment debts - General oncology therapy
Kazia Therapeutics is an Australian oncology company focused on developing drugs to treat brain cancer and other difficult-to-treat cancers. This chart shows how the biotech company, in late-stage clinical trials, manages its capital to advance its lead drug to potential approval and commercialization.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Kazia Therapeutics
Kazia Therapeutics is an Australian oncology company developing drugs to treat brain cancer and other difficult-to-treat tumors. Advancing candidates through international clinical trials is an extremely expensive process. This chart shows how the company uses debt to fund its global R&D efforts.
Market segment debt to market segment book capitalization - General oncology therapy
Kazia Therapeutics is an Australian oncology company developing drugs to treat brain cancer, one of the most complex problems in medicine. This chart shows how the company finances its expensive clinical trials, comparing its debt structure to the overall financial picture in the biotech sector.
Debt to book value of all companies in the market
Kazia Therapeutics is an Australian oncology company developing drugs to treat brain cancer. This is one of the most complex areas in medicine, requiring massive investment. How heavily does the company rely on debt? This chart of total market debt helps assess the riskiness of its biotech financial model.
P/E of the company, segment and market as a whole
P/E - Kazia Therapeutics
Kazia Therapeutics is an Australian oncology company developing drugs for the treatment of brain and other difficult-to-treat cancers. This chart shows how investors value its lead candidate. The valuation is highly sensitive to news about clinical trial results and regulatory decisions.
P/E of the market segment - General oncology therapy
Kazia Therapeutics is an Australian oncology company developing drugs to treat brain cancer and other difficult-to-treat types of cancer. This chart illustrates the average valuation in the oncology development sector, which carries both high risks and the potential rewards of developing effective drugs to treat deadly diseases.
P/E of the market as a whole
Kazia Therapeutics is an oncology company focused on developing innovative drugs for the treatment of difficult-to-treat cancers, with a particular focus on brain cancer. This chart reflects investors' overall risk appetite. It helps understand whether KZIA's valuation is based on the potential of its lead drug or whether it moves in line with overall sentiment in the biotech sector.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Kazia Therapeutics
Kazia Therapeutics is an Australian oncology company developing drugs for the treatment of brain cancer and other difficult-to-treat tumors. Its valuation is dependent on the results of clinical trials. This chart reflects investor expectations for the success of its key developments, assessing the chances of approval and future commercial demand.
%20P%2FE%20Kazia%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Kazia-Therapeutics&v=1772702534970 "Chart of the company's future (projected) P/E Kazia Therapeutics")
Future (projected) P/E of the market segment - General oncology therapy
Kazia Therapeutics is an oncology company developing drugs to treat brain cancer and other difficult-to-treat tumors. This chart reflects expectations for future profits in the sector. It helps understand how high investors' expectations are for the success of its clinical programs, particularly in areas with a critical shortage of effective treatments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-General-oncology-therapy&v=1772702534984 "Future (projected) P/E graph of the market segment - General oncology therapy")
Future (projected) P/E of the market as a whole
Kazia Therapeutics is an Australian oncology company developing drugs to treat brain cancer. Its success depends on the results of clinical trials. This chart of overall market sentiment shows how willing investors are to fund risky biotech projects, especially in complex areas like CNS oncology.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772702534985 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Kazia Therapeutics
Kazia Therapeutics is an Australian biotech company focused on oncology. Its lead drug candidate is designed to treat an aggressive form of brain cancer. Its financial metrics reflect the costs of advancing this drug through clinical trials. This chart shows the financial trajectory of a company focused on solving one of the most complex challenges in medicine.
Profit of companies in the market segment - General oncology therapy
Kazia Therapeutics is an oncology company developing drugs to treat difficult-to-treat cancers, particularly glioblastoma (brain cancer). Its success depends on the results of clinical trials. This chart reflects the overall profitability of the oncology sector, where a focus on rare and aggressive cancers can accelerate drug approvals.
Overall market profit
Kazia Therapeutics is an Australian oncology company developing drugs for the treatment of brain cancer. Its prospects depend entirely on clinical trial results and regulatory approval. This process is isolated from general economic cycles, which can be seen in this chart. The company's value lies in its intellectual property.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Kazia Therapeutics
Kazia Therapeutics is an Australian biotech company focused on drugs for the treatment of brain cancer and other oncological diseases. Future revenue depends on clinical trial data and partnerships with major pharmaceutical companies. This chart reflects analyst expectations for the commercial potential of its lead candidates.
%20profit%20of%20the%20company%20Kazia%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Kazia-Therapeutics&v=1772702535011 "Graph of future (projected) profit of the company Kazia Therapeutics")
Future (predicted) profit of companies in the market segment - General oncology therapy
Kazia Therapeutics is an Australian oncology company developing drugs for the treatment of brain cancer and other difficult-to-treat tumors. Its lead candidate is in late-stage clinical trials. This chart shows revenue projections for the oncology sector, providing context for assessing the risks and potential rewards associated with Kazia.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-General-oncology-therapy&v=1772702535016 "Graph of future (predicted) profits of companies in a market segment - General oncology therapy")
Future (predicted) profit of the market as a whole
Kazia Therapeutics is an Australian oncology company developing drugs for the treatment of brain cancer. Its prospects depend on the success of clinical trials. This economic outlook affects investors' overall risk appetite, which is critical for funding long-term biotech projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772702535037 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Kazia Therapeutics
Kazia Therapeutics is an Australian oncology company developing drugs for the treatment of brain cancer. Being in clinical trials, it has unstable revenue. This chart shows investor confidence in its lead drug. Its dynamics reflect news about trials, not current sales.
P/S market segment - General oncology therapy
Kazia Therapeutics is an Australian oncology company developing innovative cancer treatments. Its lead candidate targets glioblastoma, one of the most aggressive forms of brain cancer, for which there is a pressing need for new treatments. This chart reflects the average revenue estimate for the sector, which helps assess the potential of Kazia's developments.
P/S of the market as a whole
Kazia Therapeutics is an Australian oncology company developing drugs for the treatment of brain and other cancers. This chart illustrates that the valuation of such clinical-stage companies is based on the potential of their pipeline and the size of their addressable market, rather than on current financial performance, as is typical in the biotech sector.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Kazia Therapeutics
Kazia Therapeutics is an Australian oncology company developing drugs for the treatment of brain cancer and other difficult-to-treat cancers. Estimates based on future revenues are crucial for the company. They reflect investor expectations for the success of its lead drug in clinical trials and its potential to become a new standard of care for patients with very limited therapeutic options.
%20P%2FS%20Kazia%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Kazia-Therapeutics&v=1772702535079 "The graph of the company's future (projected) P/S Kazia Therapeutics")
Future (projected) P/S of the market segment - General oncology therapy
Kazia Therapeutics is an oncology company developing drugs to treat brain cancer and other difficult-to-treat tumors. This chart compares the company's estimated future sales with industry expectations. It shows how investors view the clinical prospects of its lead drug candidate and its potential to help patients with limited treatment options.
%20P%2FS%20market%20segment%20graph%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-General-oncology-therapy&v=1772702535107 "Future (projected) P/S market segment graph - General oncology therapy")
Future (projected) P/S of the market as a whole
Kazia Therapeutics is an Australian oncology company developing drugs to treat brain cancer and other difficult-to-treat tumors. Its future depends on the results of clinical trials in niches with high unmet needs. This chart of overall market expectations reflects investor confidence in biotech companies aiming to solve the most complex medical challenges.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772702535152 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Kazia Therapeutics
This chart illustrates the financial activity of Kazia Therapeutics, an Australian oncology company whose drugs are in clinical trials. There are no commercial sales revenues. Any revenue reflected in the chart likely comes from licensing agreements or other forms of non-dilutive financing.
Sales of companies in the market segment - General oncology therapy
Kazia Therapeutics is an Australian oncology company focused on developing drugs for the treatment of brain cancer. Being in late-stage clinical trials, it does not yet have stable revenue. Its future revenue depends on the approval and commercialization of its lead drug, paxilisib.
Overall market sales
Kazia Therapeutics is an Australian oncology company developing drugs to treat brain cancer. Its operations are entirely focused on clinical trials. This overall economic activity chart is irrelevant for a company whose mission is to offer new hope to patients with some of the most deadly forms of cancer, where the demand for effective treatment is absolute.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Kazia Therapeutics
Kazia Therapeutics is an oncology company developing drugs for the treatment of difficult-to-treat cancers, particularly brain cancer. Its future revenue is dependent on clinical trial results and regulatory approval. This chart reflects analyst expectations for the commercial potential of its lead drug candidate, paxilisib.
%20sales%20of%20the%20company%20Kazia%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Kazia-Therapeutics&v=1772702535186 "Schedule of future (projected) sales of the company Kazia Therapeutics")
Future (projected) sales of companies in the market segment - General oncology therapy
Kazia Therapeutics is an Australian oncology company developing drugs to treat brain cancer. This chart shows revenue forecasts for the entire oncology market. How do scientific breakthroughs in treating difficult-to-treat tumors influence analysts' overall growth expectations? This sets the stage for companies like Kazia.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-General-oncology-therapy&v=1772702535190 "Schedule of future (projected) sales of companies in the market segment - General oncology therapy")
Future (projected) sales of the market as a whole
Kazia Therapeutics is an oncology company developing drugs for the treatment of brain cancer. Its prospects depend entirely on the success of clinical trials and regulatory approval. The need for effective treatments for aggressive forms of cancer is not dependent on the state of the economy, so this schedule is not significant for Kazia's business.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772702535196 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Kazia Therapeutics
Kazia Therapeutics is an Australian oncology company developing drugs for the treatment of brain cancer and other difficult-to-treat tumors. This chart shows its financial trajectory during clinical trials. Profitability depends on successful research results and potential partnerships with major pharmaceutical companies to bring the drugs to the global market.
Market segment marginality - General oncology therapy
Kazia Therapeutics Limited is an Australian biotechnology company focused on developing drugs for the treatment of cancer, particularly brain tumors. This chart reflects its financial position, with profitability being a long-term goal dependent on success in complex clinical trials and regulatory approvals worldwide.
Market marginality as a whole
Kazia Therapeutics, an Australian oncology company developing drugs to treat brain cancer, is a company whose market capitalization is dependent on progress in clinical trials. This gross profitability chart reflects the global investment climate, which determines the availability of funding for late-stage biotech companies.
Employees in the company, segment and market as a whole
Number of employees in the company Kazia Therapeutics
Kazia Therapeutics is an Australian oncology company whose lead drug is being tested for the treatment of brain cancer. Its small but globally distributed team manages clinical trials. This diagram shows the compact structure typical of biotech companies, which outsource a significant portion of R&D, retaining only core expertise in-house.
Share of the company's employees Kazia Therapeutics within the market segment - General oncology therapy
Kazia Therapeutics is an oncology company focused on developing drugs for the treatment of brain cancer and other difficult-to-treat tumors. Its primary focus is clinical trials. This chart shows the company's market share in the biotech industry, reflecting the scale of its clinical programs and the size of its research team.
Number of employees in the market segment - General oncology therapy
Kazia Therapeutics is an Australian oncology company developing drugs to treat brain cancer and other difficult-to-treat tumors. This chart shows its presence in the general oncology sector. Kazia's focus on rare and aggressive cancers allows it to pursue accelerated regulatory approvals.
Number of employees in the market as a whole
Kazia Therapeutics is an Australian oncology company developing drugs for the treatment of brain cancer. Its operations are unaffected by general economic cycles. This chart shows the US labor market, but Kazia illustrates the global nature of biotechnology, where employment is driven by the universal need for new drugs and research funding.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Kazia Therapeutics (KZIA)
Kazia Therapeutics is an Australian biotech focused on cancer treatment, particularly brain tumors. They operate with a very compact team. This chart shows the significant market value (expected) generated by each employee. This reflects the high valuation of their leading drugs and their potential in the oncology market.
%20of%20the%20company%20Kazia%20Therapeutics%20(KZIA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Kazia-Therapeutics-KZIA&v=1772702535266 "Chart of market capitalization per employee (in thousands of dollars) of the company Kazia Therapeutics (KZIA)")
Market capitalization per employee (in thousands of dollars) in the market segment - General oncology therapy
Kazia Therapeutics (KZIA) is an Australian oncology company developing drugs for brain cancer. The market capitalization per employee in this segment reflects its estimated breakthrough potential. This high value may be due to the fact that their key drug, paxilisib, is showing promising results in the treatment of glioblastoma, one of the most deadly forms of cancer.
%20by%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-General-oncology-therapy&v=1772702535272 "Market capitalization per employee (in thousands of dollars) by market segment - General oncology therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Kazia Therapeutics is an Australian oncology company developing drugs for the treatment of brain cancer. Its valuation is based on clinical trial results. The chart shows a high cost per employee, as the market sees great potential in its lead drug, which targets one of the most difficult-to-treat forms of cancer.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772702535276 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Kazia Therapeutics (KZIA)
Kazia Therapeutics is an Australian biotech company focused on oncology, specifically brain cancer. This chart reflects the investment phase. Negative profit per employee is the norm for an R&D company, reflecting the capital invested in each researcher to fund expensive clinical trials.
%20Chart%20Kazia%20Therapeutics%20(KZIA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Kazia-Therapeutics-KZIA&v=1772702535285 "Company Profit Per Employee (in thousands of dollars) Chart Kazia Therapeutics (KZIA)")
Profit per employee (in thousands of dollars) in the market segment - General oncology therapy
Kazia Therapeutics is an Australian oncology company developing drugs to treat brain cancer. In this complex biotech niche, a small but focused team can achieve breakthroughs. This chart shows the financial return per employee, an important indicator of the effectiveness of their R&D strategy compared to other oncology players.
%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-General-oncology-therapy&v=1772702535290 "Chart of profit per employee (in thousands of dollars) in the market segment - General oncology therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Kazia Therapeutics is an Australian oncology company focused on treating brain cancer (glioblastoma). It's an R&D company in the clinical trials stage. This chart, showing average market profitability, helps to understand the contrast with biotech, which employs a small team of scientists and has a dramatically different financial return (often a loss) per employee.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772702535298 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Kazia Therapeutics (KZIA)
Kazia Therapeutics is an oncology company developing drugs to treat brain cancer. At the clinical stage, this figure is negligible. It reflects the enormous stakes in biotech: a successful drug in such a complex field could become a blockbuster and lead to explosive revenue growth per research team member.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Kazia-Therapeutics-KZIA&v=1772702535308 "Sales chart per company employee Kazia Therapeutics (KZIA)")
Sales per employee in the market segment - General oncology therapy
Kazia Therapeutics is an Australian clinical-stage biotech focused on oncology, specifically brain cancer (glioblastoma). They have no commercial revenue. This chart, showing the average revenue in the sector, serves as a benchmark for KZIA's R&D staffing efficiency compared to other biotechs.
Sales per employee for the market as a whole
Kazia Therapeutics is an Australian biotech company focused on cancer treatment, particularly brain tumors (glioblastomas). Their core business is R&D and clinical trials. This indicator reflects their pre-commercial phase. The company is investing in science in hopes of bringing a life-saving drug to market.
Short shares by company, segment and market as a whole
Shares shorted by company Kazia Therapeutics (KZIA)
Kazia (KZIA) is an Australian biotech company focused on cancer treatment, particularly brain tumors. This chart shows the volume of bearish bets. Shorts may be driven by previous clinical trial failures or skepticism that its drugs will outperform existing treatment standards.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Kazia-Therapeutics-KZIA&v=1772702535321 "Short Shares Chart for the Company Kazia Therapeutics (KZIA)")
Shares shorted by market segment - General oncology therapy
Kazia Therapeutics (KZIA) is an Australian oncology company developing drugs to treat complex forms of cancer, particularly brain tumors (glioblastomas). This chart aggregates short positions across the entire oncology biotech sector. It reflects the general investor skepticism regarding the risks and high mortality rates of projects in this industry.
Shares shorted by the overall market
Kazia (KZIA) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing KZIA won't be able to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Kazia Therapeutics (KZIA)
Kazia Therapeutics (KZIA) is an Australian biotech focused on oncology, specifically brain cancer (glioblastoma). This is an area of high medical need. This chart measures the rate of price change. It shows when enthusiasm (above 70) about trial data or disappointment (below 30) peaks.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Kazia-Therapeutics-KZIA&v=1772702535340 "RSI 14 indicator chart for the company's stock Kazia Therapeutics (KZIA)")
RSI 14 Market Segment - General oncology therapy
Kazia Therapeutics is an Australian oncology company developing drugs to treat difficult-to-treat cancers, particularly brain tumors (glioblastomas). This chart shows the overall sentiment in the oncology biotech sector. It helps us understand whether KZIA's performance is driven by its clinical data or is a general "wave" across the industry.
RSI 14 for the overall market
Kazia Therapeutics (KZIA) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic poses the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast KZIA (Kazia Therapeutics)
Kazia Therapeutics is an Australian oncology company whose lead drug (paxalisib) is being developed to treat the most aggressive form of brain cancer, glioblastoma. This chart shows the speculative average price target from analysts, which is almost entirely dependent on their belief in the success of the drug's clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-KZIA-Kazia-Therapeutics&v=1772702535370 "A chart showing analyst consensus forecasts for the expected stock price. KZIA (Kazia Therapeutics)")
The difference between the consensus estimate and the actual stock price KZIA (Kazia Therapeutics)
Kazia is an Australian biotech focused on fighting the most aggressive form of brain cancer, glioblastoma. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their view of the company's prospects in this challenging area of oncology.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-KZIA-Kazia-Therapeutics&v=1772702535381 "A chart showing the difference between the consensus forecast and the actual stock price. KZIA (Kazia Therapeutics)")
Analyst consensus forecast for stock prices by market segment - General oncology therapy
Kazia (KZIA) is an Australian biotech company focused on developing drugs for complex types of brain cancer (glioblastoma). This is high-risk R&D. This chart shows analysts' overall expectations for the oncology sector. It reflects whether experts believe a breakthrough in brain cancer treatment is possible or whether they view the sector as an R&D "graveyard."
Analysts' consensus forecast for the overall market share price
Kazia Therapeutics is an Australian biotech company specializing in developing drugs to treat difficult-to-treat cancers, particularly brain tumors. This chart reflects the overall market "risk appetite." For Kazia, a high-risk clinical-stage company, overall market optimism (risk appetite) is critical for attracting capital for R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Kazia Therapeutics
Kazia is an Australian biotech R&D company focused on complex cancers. Their flagship R&D project (Paxalisib) targets brain cancer (glioblastoma), one of the most deadly and difficult-to-treat tumors. This chart is a pure indicator of their faith in R&D. It doesn't reflect revenue, but rather a speculative assessment of their (very risky) pipeline and their clinical trial data.
AKIMA Market Segment Index - General oncology therapy
Kazia Therapeutics (KZIA) is an Australian oncology company tackling one of the most challenging cancers: brain cancer (glioblastoma). Their lead drug, Paxalisib, is designed to cross the blood-brain barrier and attack the tumor. This chart shows the segment average. It helps investors assess how Kazia's risks compare to the oncology industry average.
The AKIM Index for the overall market
Kazia Therapeutics is an oncology company focused on developing drugs for the treatment of brain cancer (glioblastoma). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this niche research company stacks up against overall economic trends and the complexity of CNS treatments.
